Literature DB >> 31537715

Genetic predictors of survival in behavioral variant frontotemporal degeneration.

Carrie Caswell1, Corey T McMillan1, Sharon X Xie1, Vivianna M Van Deerlin1, EunRan Suh1, Edward B Lee1, John Q Trojanowski1, Virginia M-Y Lee1, David J Irwin1, Murray Grossman1, Lauren M Massimo2.   

Abstract

OBJECTIVE: To determine autosomal dominant genetic predictors of survival in individuals with behavioral variant frontotemporal degeneration (bvFTD).
METHODS: A retrospective chart review of 174 cases with a clinical phenotype of bvFTD but no associated elementary neurologic features was performed, with diagnosis either autopsy-confirmed (n = 57) or supported by CSF evidence of non-Alzheimer pathology (n = 117). Genetic analysis of the 3 most common genes with pathogenic autosomal dominant mutations associated with frontotemporal degeneration was performed in all patients, which identified cases with C9orf72 expansion (n = 28), progranulin (GRN) mutation (n = 12), and microtubule-associated protein tau (MAPT) mutation (n = 10). Cox proportional hazards regressions were used to test for associations between survival and mutation status, sex, age at symptom onset, and education.
RESULTS: Across all patients with bvFTD, the presence of a disease-associated pathogenic mutation was associated with shortened survival (hazard ratio [HR] 2.164, 95% confidence interval [CI] 1.391, 3.368). In separate models, a GRN mutation (HR 2.423, 95% CI 1.237, 4.744), MAPT mutation (HR 8.056, 95% CI 2.938, 22.092), and C9orf72 expansion (HR 1.832, 95% CI 1.034, 3.244) were each individually associated with shorter survival relative to sporadic bvFTD. A mutation on the MAPT gene results in an earlier age at onset than a C9orf72 expansion or mutation on the GRN gene (p = 0.016).
CONCLUSIONS: Our findings suggest that autosomal dominantly inherited mutations, modulated by age at symptom onset, associate with shorter survival among patients with bvFTD. We suggest that clinical trials and clinical management should consider mutation status and age at onset when evaluating disease progression.
© 2019 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31537715      PMCID: PMC6946477          DOI: 10.1212/WNL.0000000000008387

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  35 in total

1.  Brain atrophy over time in genetic and sporadic frontotemporal dementia: a study of 198 serial magnetic resonance images.

Authors:  J L Whitwell; B F Boeve; S D Weigand; M L Senjem; J L Gunter; M C Baker; M DeJesus-Hernandez; D S Knopman; Z K Wszolek; R C Petersen; R Rademakers; C R Jack; K A Josephs
Journal:  Eur J Neurol       Date:  2015-02-12       Impact factor: 6.089

2.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine.

Authors:  David J Irwin; Nigel J Cairns; Murray Grossman; Corey T McMillan; Edward B Lee; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  Acta Neuropathol       Date:  2014-12-31       Impact factor: 17.088

3.  Comparison of cerebrospinal fluid levels of tau and Aβ 1-42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms.

Authors:  David J Irwin; Corey T McMillan; Jon B Toledo; Steven E Arnold; Leslie M Shaw; Li-San Wang; Vivianna Van Deerlin; Virginia M-Y Lee; John Q Trojanowski; Murray Grossman
Journal:  Arch Neurol       Date:  2012-08

4.  Survival profiles of patients with frontotemporal dementia and motor neuron disease.

Authors:  William T Hu; Harro Seelaar; Keith A Josephs; David S Knopman; Bradley F Boeve; Eric J Sorenson; Leo McCluskey; Lauren Elman; Helenius J Schelhaas; Joseph E Parisi; Benno Kuesters; Virginia M-Y Lee; John Q Trojanowski; Ronald C Petersen; John C van Swieten; Murray Grossman
Journal:  Arch Neurol       Date:  2009-11

5.  Mendelian forms of disease and age at onset affect survival in frontotemporal dementia.

Authors:  Maura Cosseddu; Alberto Benussi; Stefano Gazzina; Rosanna Turrone; Silvana Archetti; Elisa Bonomi; Giorgio Biasiotto; Isabella Zanella; Raffaele Ferrari; Maria S Cotelli; Antonella Alberici; Alessandro Padovani; Barbara Borroni
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-10-08       Impact factor: 4.092

6.  Development and validation of pedigree classification criteria for frontotemporal lobar degeneration.

Authors:  Elisabeth M Wood; Dana Falcone; Eunran Suh; David J Irwin; Alice S Chen-Plotkin; Edward B Lee; Sharon X Xie; Vivianna M Van Deerlin; Murray Grossman
Journal:  JAMA Neurol       Date:  2013-11       Impact factor: 18.302

7.  Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics.

Authors:  Jennifer L Whitwell; Stephen D Weigand; Bradley F Boeve; Matthew L Senjem; Jeffrey L Gunter; Mariely DeJesus-Hernandez; Nicola J Rutherford; Matthew Baker; David S Knopman; Zbigniew K Wszolek; Joseph E Parisi; Dennis W Dickson; Ronald C Petersen; Rosa Rademakers; Clifford R Jack; Keith A Josephs
Journal:  Brain       Date:  2012-03       Impact factor: 13.501

8.  Patterns of gray matter atrophy in genetic frontotemporal dementia: results from the GENFI study.

Authors:  David M Cash; Martina Bocchetta; David L Thomas; Katrina M Dick; John C van Swieten; Barbara Borroni; Daniela Galimberti; Mario Masellis; Maria Carmela Tartaglia; James B Rowe; Caroline Graff; Fabrizio Tagliavini; Giovanni B Frisoni; Robert Laforce; Elizabeth Finger; Alexandre de Mendonça; Sandro Sorbi; Martin N Rossor; Sebastien Ourselin; Jonathan D Rohrer
Journal:  Neurobiol Aging       Date:  2017-10-19       Impact factor: 4.673

Review 9.  The Genetics of Monogenic Frontotemporal Dementia.

Authors:  Leonel T Takada
Journal:  Dement Neuropsychol       Date:  2015 Jul-Sep

10.  Factors influencing the age at onset in familial frontotemporal lobar dementia: Important weight of genetics.

Authors:  Mathieu Barbier; Agnès Camuzat; Marion Houot; Fabienne Clot; Paola Caroppo; Clémence Fournier; Daisy Rinaldi; Florence Pasquier; Didier Hannequin; Jérémie Pariente; Kathy Larcher; Alexis Brice; Emmanuelle Génin; Audrey Sabbagh; Isabelle Le Ber
Journal:  Neurol Genet       Date:  2017-12-13
View more
  5 in total

1.  Differences in Motor Features of C9orf72, MAPT, or GRN Variant Carriers With Familial Frontotemporal Lobar Degeneration.

Authors:  Philip Wade Tipton; Angela B Deutschlaender; Rodolfo Savica; Michael G Heckman; Danielle E Brushaber; Bradford C Dickerson; Ralitza H Gavrilova; Daniel H Geschwind; Nupur Ghoshal; Jonathan Graff-Radford; Neill R Graff-Radford; Murray Grossman; Ging-Yuek R Hsiung; Edward D Huey; David John Irwin; David T Jones; David S Knopman; Scott M McGinnis; Rosa Rademakers; Eliana Marisa Ramos; Leah K Forsberg; Hilary W Heuer; Chiadi Onyike; Carmela Tartaglia; Kimiko Domoto-Reilly; Erik D Roberson; Mario F Mendez; Irene Litvan; Brian S Appleby; Ian Grant; Daniel Kaufer; Adam L Boxer; Howard J Rosen; Brad F Boeve; Zbigniew K Wszolek
Journal:  Neurology       Date:  2022-07-05       Impact factor: 11.800

Review 2.  Frontotemporal degeneration genetic risk loci and transcription regulation as a possible mechanistic link to disease risk.

Authors:  Russell P Sawyer; Hillarey K Stone; Hanan Salim; Xiaoming Lu; Matthew T Weirauch; Leah Kottyan
Journal:  Medicine (Baltimore)       Date:  2022-10-14       Impact factor: 1.817

3.  Common genetic variation is associated with longitudinal decline and network features in behavioral variant frontotemporal degeneration.

Authors:  Lauren Massimo; Lior Rennert; Sharon X Xie; Christopher Olm; Jessica Bove; Vivianna Van Deerlin; David J Irwin; Murray Grossman; Corey T McMillan
Journal:  Neurobiol Aging       Date:  2021-08-03       Impact factor: 4.673

4.  Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve.

Authors:  Ignacio Illán-Gala; Kaitlin B Casaletto; Sergi Borrego-Écija; Eider M Arenaza-Urquijo; Amy Wolf; Yann Cobigo; Sheng Yang M Goh; Adam M Staffaroni; Daniel Alcolea; Juan Fortea; Rafael Blesa; Jordi Clarimon; Maria Florencia Iulita; Anna Brugulat-Serrat; Albert Lladó; Lea T Grinberg; Katherine Possin; Katherine P Rankin; Joel H Kramer; Gil D Rabinovici; Adam Boxer; William W Seeley; Virginia E Sturm; Maria Luisa Gorno-Tempini; Bruce L Miller; Raquel Sánchez-Valle; David C Perry; Alberto Lleó; Howard J Rosen
Journal:  Alzheimers Dement       Date:  2021-02-16       Impact factor: 16.655

5.  Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations.

Authors:  Christian Hinderer; Rod Miller; Cecilia Dyer; Julia Johansson; Peter Bell; Elizabeth Buza; James M Wilson
Journal:  Ann Clin Transl Neurol       Date:  2020-09-16       Impact factor: 4.511

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.